TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03010488

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Morning Light Therapy
Description: 10,000 Lux light for 30 minutes through a light box each morning at patient's desired wake up time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Morning Light Therapy
Description: 10,000 Lux light for 30 minutes through a light box each morning at patient's desired wake up time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assigned Sleep Times
Description: Sleep times will be assigned to subjects that will allow them to drive their regular sleep times closer to those they determine to be optimal at study initiation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned Sleep Times
Description: Sleep times will be assigned to subjects that will allow them to drive their regular sleep times closer to those they determine to be optimal at study initiation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goggles
Description: Subjects will wear goggles during saliva collection and Bright Light Therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goggles
Description: Subjects will wear goggles during saliva collection and Bright Light Therapy
Study: NCT02713074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: povidone-iodine
Description: The patients will be subjected to povidone-iodine (Betadine7.5%) for vaginal cleaning before office hysteroscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: The patients will be subjected to normal saline (Sod. Chloride 0.9%, Nile) for vaginal cleaning
Study: NCT04129437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Weight based ibuprofen dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Weight based ibuprofen dosing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic manipulative treatment
Description: Low velocity osteopathic manipulative treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic manipulative treatment
Description: Low velocity osteopathic manipulative treatment
Study: NCT03264053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Socket shield
Description: Socket shield is the Removal of the lingual portion of the anterior root thus retaining the lingual portion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional immediate implantation
Description: Conventional immediate implantation
Study: NCT01737593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Study: NCT03956537

Intervention type: DEVICE
Intervention: NEO Pedicle Screw System™
Description: The NEO Pedicle Screw System™ is intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion.

Intervention type: DEVICE
Intervention: NEO Pedicle Screw System™
Description: The NEO Pedicle Screw System™ is intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion.

Intervention type: DEVICE
Intervention: Neo Cage System™
Description: Neo Cage System™ is intended to be used with bone graft material to facilitate interbody fusion and to be used with the NEO Pedicle Screw System™
Study: NCT01713101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early intravenous tranexamic acid administration
Description: Initial history taking and physical examination --\> enrollment --\> 1g bolus over 10 minutes followed slow infusion over 8 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02683603

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AS colistin and imipenem
Description: colimycin (colistin) powder (1 million units (MU) by flakon) by AS route in addition to imipenem

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV colistin  and imipenem .
Description: colimycin (colistin) powder (1 MU by flakon) by intravenous route in addition to imipenem

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AS colimycin (colistin)
Description: nebulisation of colimycin (colistin) for 30 minutes 3 times per day during at least 14 days. Nebulisation was made via an ultrasonic vibrating plates nebulizer (Aeroneb Pro® Aerogen Nektar Corporation, Galway, Ireland).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV colimycin (colistin)
Description: intravenous colimycin (colistin) : 9 MU during 60 minutes followed by 4.5 million units 2 times per day
Study: NCT03773107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Oral JAK inhibitor

Intervention type: DRUG
Group type: OTHER
Intervention: Ruxolitinib
Description: Oral JAK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: glucocorticoid

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: glucocorticoid
Study: NCT02683603

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AS colistin and imipenem
Description: IV imipenem 1 g three times per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV colistin and imipenem
Description: IV imipenem 1 g three times per day
Study: NCT01666340

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise intervention
Description: Group asked to perform exercise at a given moderate intensity for a set time

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Group asked to perform exercise at a given moderate intensity for a set time

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise intervention
Description: High intensity exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: High intensity exercise
Study: NCT01788436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Test Battery 1
Description: The Cognitive Test Battery 1 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Pattern/Sequence Learning Task (PLT_Impl); Verbal Learning Test (VLT); Figure drawing; Mirror Drawing; Explicit Pattern Learning Task (PLT_Expl); Delayed Recall and Recognition Test; and Pursuit rotor.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Test Battery 1
Description: The Cognitive Test Battery 1 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Pattern/Sequence Learning Task (PLT_Impl); Verbal Learning Test (VLT); Figure drawing; Mirror Drawing; Explicit Pattern Learning Task (PLT_Expl); Delayed Recall and Recognition Test; and Pursuit rotor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Test Battery 1
Description: The Cognitive Test Battery 1 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Pattern/Sequence Learning Task (PLT_Impl); Verbal Learning Test (VLT); Figure drawing; Mirror Drawing; Explicit Pattern Learning Task (PLT_Expl); Delayed Recall and Recognition Test; and Pursuit rotor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Test Battery 2
Description: The Cognitive Test Battery 2 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Learning Retention Test; Hopkins Verbal Learning Test (HVLT); Figure drawing; Mirror Drawing; Explicit Learning Retention Test; Instrumental Learning Task; Pursuit rotor; and Sensory Motor Interception Adaptation Task.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Test Battery 2
Description: The Cognitive Test Battery 2 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Learning Retention Test; Hopkins Verbal Learning Test (HVLT); Figure drawing; Mirror Drawing; Explicit Learning Retention Test; Instrumental Learning Task; Pursuit rotor; and Sensory Motor Interception Adaptation Task.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Test Battery 2
Description: The Cognitive Test Battery 2 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Learning Retention Test; Hopkins Verbal Learning Test (HVLT); Figure drawing; Mirror Drawing; Explicit Learning Retention Test; Instrumental Learning Task; Pursuit rotor; and Sensory Motor Interception Adaptation Task.
Study: NCT03464292

Intervention type: DRUG
Intervention: Capsaicin Patch 8% or 0.1% Capsaicin Cream
Description: 0.1 ml of 8% capsaicin topical patch or 0.1% capsaicin cream

Intervention type: OTHER
Intervention: Vehicle Patch
Description: Control patch will be the same topical solution but will not contain capsaicin.
Study: NCT04028271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comfort-in injection system
Description: local anesthesia during dental treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional injection with dental needle
Description: for local anesthesia during dental treatment
Study: NCT01734889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: Oral suspension
Study: NCT02842034

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Stimulate the dorsomedial prefrontal cortex for 4 weeks.
Study: NCT03757104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPIC-HIV
Description: Men in these communities are eligible to receive a tablet-based male-sensitive HIV decision support app (EPIC-HIV 1)to encourage them to test for HIV at home. If diagnosed with HIV and do not link to care within a month of HIV test, they become eligible to receive a tablet-based male HIV specific decision support app (EPIC-HIV 2) to encourage them to link to HIV care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: micro-incentive and EPIC-HIV
Description: micro-incentives: Residents in these communities are eligible to receive a R50 food voucher conditional on undergoing a home-based HIV test. If diagnosed with HIV, residents are eligible to receive a second R50 food voucher when they link to care within 6 weeks of the HIV test.~EPIC-HIV 1:~Men in these communities are eligible to receive a tablet-based male-sensitive HIV specific decision support app (EPIC-HIV 1) to encourage them to test for HIV at home. If diagnosed with HIV and do not link to care within a month of HIV test, they become eligible to receive a tablet-based male HIV specific decision support app (EPIC-HIV 2) to encourage them to link to HIV care.
Study: NCT01431404

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept (Enbrel)
Description: prefilled syringe, SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HD203
Description: HD203, prefilled syringe, SC injection
Study: NCT01211379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FLU-FOBT Program
Description: Primary care patients who came in for flu shots were assessed by nurses for colorectal cancer screening eligibility and offered FOBT if due.
Study: NCT02842034

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Stimulate the dorsomedial prefrontal cortex for 4 weeks.
Study: NCT02598765

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Trabeculectomy
Description: Fornix-based trabeculectomy with a 3x4 mm scleral flap.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microtrabeculectomy
Description: Fornix-based trabeculectomy with a 2x2 mm scleral flap.
Study: NCT01865331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Single dose administered subcutaneously (s.c., under the skin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Single dose administered subcutaneously (s.c., under the skin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Single dose administered subcutaneously (s.c., under the skin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart 50
Description: Single dose of IDegAsp 50 administered subcutaneously (s.c., under the skin)
Study: NCT04999579

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T scan
Description: Occlusal load analysis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T scan
Description: Occlusal load analysis
Study: NCT01397578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MABT5102A
Description: Repeating subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MABT5102A
Description: Repeating intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Repeating subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Repeating intravenous infusion
Study: NCT02338102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline mixture
Description: premeasured salt packets mixed with distilled water
Study: NCT03356184

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Rhea Vital Sign Vigilance Device Group
Description: The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Earlysense System Device Group
Description: The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
Study: NCT04102969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benson Relaxation Technique
Description: Benson relaxation technique will be performed two times a day for 10 minutes during the study period ( two months) for the intervention group.

Intervention type: OTHER
Group type: OTHER
Intervention: Nutrition Package Session
Description: A nutrition package session will be given to the control group.
Study: NCT01113970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indibulin
Description: Indibulin given orally once a day for 5 days followed by a 9 day rest
Study: NCT02576314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sofosbuvir and daclatasvir
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60 mg tablet administered orally once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ledipasvir/sofosbuvir
Description: Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally.~once daily;
Study: NCT02721537

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Riboside
Description: Three capsules, twice per day for 84 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Three matching capsules, twice per day for 84 days
Study: NCT01583374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast tablet 20 mg
Description: Apremilast 20 mg was taken orally twice a day (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast tablet 30 mg BID
Description: Apremilast 30 mg was taken orally twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically matched placebo tablets were taken orally twice a day during the placebo controlled phase.
Study: NCT03300557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02263352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lycored soft gels Jagsonpal Pharma, Systemic 8mgms/day
Description: Lycopene 8mgms taken orally ,one per day for two months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Scaling and root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Scaling and root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus
Study: NCT03661567

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chest radiation
Description: split-course chest radiation

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: chest radiation
Description: split-course chest radiation
Study: NCT00460343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: extensive implementation programme
Description: experimental pharmacists follow an extensive implementation programme. They attend two interactive half a day educational meetings tailored to individual needs: one at start of the intervention, and one in May or September 2007. Special attention is given to multiprofessional cooperation with general practitioners and nurse practitioners. Additionally, guided by their own project planning pharmacists receive three or more telephone calls, both as a reminder, feedback, and in order to investigate whether they need any more help.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: pharmacists only receive a written manual with instructions to implement the patient compliance intervention.
Study: NCT02254031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bivatuzumab mertansine
Study: NCT01986062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR11

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02482584

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP intervention

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Control
Study: NCT01209026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (200 mcg)/GW642444 (25mcg) combination
Description: Novel dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (400 mcg)/GW642444 (50mcg) combination
Description: Novel dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Inhaler
Description: Matching placebo Novel dry powder inhaler. Lactose monohydrate and magnesium stearate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Inhaler
Description: Matching placebo Novel dry powder inhaler. Lactose monohydrate and magnesium stearate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Inhaler
Description: Matching placebo Novel dry powder inhaler. Lactose monohydrate and magnesium stearate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400mg
Description: Film coated oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin placebo
Description: Film coated oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin placebo
Description: Film coated oral tablet
Study: NCT03661567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent chemotherapy
Description: weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: concurrent chemotherapy
Description: weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone after the first course of radiation, once a day, 32 milligram (mg) for 7 days, 24 mg for the next 7 days, then 16mg for 7 days, and 8 mg for the last 7 days.
Study: NCT03260049

Intervention type: PROCEDURE
Intervention: pars plana vitrectomy
Description: pars plana vitrectomy

Intervention type: PROCEDURE
Intervention: pars plana vitrectomy
Description: pars plana vitrectomy
Study: NCT04170972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute exercise
Description: One hour of acute one-legged knee-extensor exercise followed by 3 hours recovery and 2 hours insulin (1.5 mU/min/kg) stimulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute exercise
Description: One hour of acute one-legged knee-extensor exercise followed by 3 hours recovery and 2 hours insulin (1.5 mU/min/kg) stimulation.
Study: NCT00003590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea
Description: 20 mg/kg/day PO
Study: NCT02463890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Study: NCT03463005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Royal jelly
Description: The study subjects in the Royal jelly group used 10 ml of the vaginal Royal jell few minutes before and few minutes after intercourse one day after the end of menstruation for two weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IUI
Description: Subjects in IUI group received 75 units of FSH from the second day of the cycle.
Study: NCT01131819

Intervention type: DEVICE
Group type: OTHER
Intervention: Nintendo Wii fit ™ balance board
Description: Nintendo Wii fit ™ balance board will be introduced for a period of at least 20 minutes but not greater than 30 minutes per day to all the subjects for a minimum of 6 times in two weeks and a maximum of 18 times in 6 weeks.